Complete tumor regression under given therapeutic regimens was achieved in a subset of animals only, although, overall, a combination of AZD4635 and an anti-PD-L1 mAb demonstrated highest efficacy across studies (Figures 1B, C). This evidence concerns the gene CD274 and neoplasm.